AMENDMENT TO JOINT VENTURE CONTRACTJoint Venture Contract • September 26th, 2018 • Aridis Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS AMENDMENT TO JOINT VENTURE CONTRACT (this “Amendment”) is entered into on August 6th, 2018 (the “Execution Date”), by and Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (“Hepalink”), and Aridis Pharmaceuticals Inc. (“Aridis”).
AMENDED AND RESTATED TECHNOLOGY LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN SHENZHEN ARIMAB BIOPHARMACEUTICALS CO., LTD. AND ARIDIS PHARMACEUTICALS,INC. Date: August 6, 2018Technology License and Collaboration Agreement • September 26th, 2018 • Aridis Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amended and Restated Technology License and Collaboration Agreement (this “Agreement”) is entered into as of August 6, 2018 (the “Execution Date”) by and between Shenzhen Arimab Biopharmaceuticals Co., Ltd., a corporation organized under the laws of the PRC having a place of business at Room 5044, No. 21, Langshan Lu, Song Ping Shan, Nanshan District, Shenzhen, China (“Company”), and Aridis Pharmaceuticals, Inc., a corporation organized under the laws of Delaware, USA, having a place of business at 5941 Optical Court, San Jose, California 95138, the USA (“Licensor”). Company and Licensor may be referred to herein respectively as a “Party” or collectively as “Parties.”
